The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, has led to a significant paradigm shift in the management of patients with thoracic cancers. Elucidation of biologic mechanisms that underpin carcinogenetic potential and metastatic behavior has led to an inevitable explosion in the development of effective targeted agents and immunotherapy strategies, many of which have been proven to be more effective and less toxic therapeutic approaches.